The effect of proton pump inhibitors on survival outcomes in advanced hepatocellular carcinoma treated with sorafenib.
Warit RuanglertboonMichael J SorichJessica M LoganAndrew RowlandAshley M HopkinsPublished in: Journal of cancer research and clinical oncology (2020)
In a large high-quality dataset, PPI use was not observed to compromise the survival outcomes of advanced HCC patients initiated on sorafenib.